This company has been marked as potentially delisted and may not be actively trading. Albireo Pharma (ALBO) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ALBO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Albireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and ReliabilityMay 6, 2024 | businesswire.comProspect Park II in Fort LauderdaleJanuary 19, 2024 | bizjournals.comALBO Historical DataOctober 1, 2023 | investing.comAlbireo Pharma (NASDAQ:ALBO) Coverage Initiated by Analysts at StockNews.comMarch 30, 2023 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Receives Consensus Rating of "Hold" from AnalystsMarch 27, 2023 | marketbeat.comStockNews.com Begins Coverage on Albireo Pharma (NASDAQ:ALBO)March 14, 2023 | marketbeat.comIpsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolioMarch 4, 2023 | finanznachrichten.deFederated Hermes Inc. Has $43.72 Million Position in Albireo Pharma, Inc. (NASDAQ:ALBO)March 3, 2023 | marketbeat.comShort Interest in Albireo Pharma, Inc. (NASDAQ:ALBO) Declines By 19.8%March 3, 2023 | marketbeat.comTower Research Capital LLC TRC Boosts Stock Holdings in Albireo Pharma, Inc. (NASDAQ:ALBO)March 1, 2023 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Stock Position Trimmed by ExodusPoint Capital Management LPFebruary 27, 2023 | marketbeat.comALBO Albireo Pharma, Inc.February 25, 2023 | seekingalpha.comConnor Clark & Lunn Investment Management Ltd. Acquires New Shares in Albireo Pharma, Inc. (NASDAQ:ALBO)February 24, 2023 | marketbeat.comAlbireo Pharma, Inc. (ALBO)February 18, 2023 | uk.finance.yahoo.comPrudential Financial Inc. Sells 41,800 Shares of Albireo Pharma, Inc. (NASDAQ:ALBO)February 16, 2023 | marketbeat.comAlbireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBOFebruary 14, 2023 | marketwatch.comFDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeFebruary 14, 2023 | finance.yahoo.comDekaBank Deutsche Girozentrale Grows Position in Albireo Pharma, Inc. (NASDAQ:ALBO)January 27, 2023 | marketbeat.comALBO.PH - | Stock Price & Latest News | ReutersJanuary 24, 2023 | reuters.comWhy These Two Biotech Stocks Blasted Higher This WeekJanuary 21, 2023 | finance.yahoo.comHC Wainwright Weighs in on Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)January 13, 2023 | marketbeat.comCowen & Co. Downgrades Albireo Pharma: Here's What You Need To KnowJanuary 11, 2023 | msn.comAnalysts move to downgrade Albireo Pharma after Ipsen's proposed acquisitionJanuary 11, 2023 | msn.comAlbireo Pharma Spikes On Agreement To Be Acquired By IpsenJanuary 11, 2023 | nasdaq.comExpert Ratings for Albireo PharmaJanuary 11, 2023 | markets.businessinsider.comAlbireo Pharma (NASDAQ:ALBO) Rating Lowered to Neutral at GuggenheimJanuary 11, 2023 | marketbeat.comEquities Analysts Issue Forecasts for Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)January 10, 2023 | marketbeat.comShareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with IpsenJanuary 9, 2023 | benzinga.comALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to ShareholdersJanuary 9, 2023 | technews.tmcnet.comFrance-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, PipelineJanuary 9, 2023 | finance.yahoo.comAlbireo: Slowly Capturing Some Of The Liver Disease MarketJanuary 2, 2023 | seekingalpha.comWe're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn RateDecember 21, 2022 | finance.yahoo.comAlbireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsDecember 6, 2022 | finance.yahoo.comReimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2November 30, 2022 | finance.yahoo.comFY2022 Earnings Estimate for Albireo Pharma, Inc. (NASDAQ:ALBO) Issued By William BlairNovember 14, 2022 | marketbeat.comAlbireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investorsNovember 10, 2022 | finance.yahoo.comAlbireo to Participate in Jefferies London Healthcare ConferenceNovember 9, 2022 | finance.yahoo.comAlbireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | seekingalpha.comAlbireo Reports Q3 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comAlbireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | finance.yahoo.comBylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNovember 7, 2022 | finance.yahoo.comAlbireo Announces 2022 SPARK Grant WinnersNovember 3, 2022 | finance.yahoo.comAlbireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNovember 2, 2022 | finance.yahoo.comAlbireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022November 1, 2022 | finance.yahoo.comAlbireo to Report Q3 2022 Financial Results on November 8, 2022October 31, 2022 | finance.yahoo.comAnalysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's PenetrationOctober 25, 2022 | finance.yahoo.comInsider Selling: Albireo Pharma, Inc. (NASDAQ:ALBO) CEO Sells 919 Shares of StockOctober 25, 2022 | marketbeat.comAlbireo Pharma (NASDAQ:ALBO) Price Target Raised to $59.00 at GuggenheimAlbireo Pharma (NASDAQ:ALBO) Price Target Raised to $59.00 at Guggenheim...October 17, 2022 | marketbeat.comAlbireo Pharma, Inc. (NASDAQ:ALBO) Short Interest Down 13.3% in SeptemberAlbireo Pharma, Inc. (NASDAQ:ALBO) Short Interest Down 13.3% in September...October 15, 2022 | marketbeat.comQ3 2022 EPS Estimates for Albireo Pharma, Inc. (NASDAQ:ALBO) Increased by AnalystOctober 14, 2022 | marketbeat.com Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALBO Media Mentions By Week ALBO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALBO News Sentiment▼0.200.99▲Average Medical News Sentiment ALBO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALBO Articles This Week▼00▲ALBO Articles Average Week Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MOR News CALT News ZYME News CMRX News CDMO News MBX News RVNC News CKPT News AVTE News TSVT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALBO) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Albireo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
